NEW YORK, April 26, 2017 /PRNewswire/ --
Four equities have been lined up for review on Stock-Callers.com today, and they are: Alere Inc. (NYSE: ALR), OpGen Inc. (NASDAQ: OPGN), Novadaq Technologies Inc. (NASDAQ: NVDQ), and PRA Health Sciences Inc. (NASDAQ: PRAH). These stocks belong to the Medical Laboratories and Research category, which is very small from a dividend perspective. Companies in this group focus on performing various tests on patients that give them information on the health of patients. Learn more about these stocks by downloading their free report at:
On Tuesday, shares in Waltham, Massachusetts headquartered Alere Inc. recorded a trading volume of 1.60 million shares, which was above their three months average volume of 1.27 million shares. The stock ended the session 0.16% higher at $49.12. The Company's shares have gained 25.53% in the last one month, 24.35% over the previous three months, and 26.05% on an YTD basis. The stock is trading 20.70% above its 50-day moving average and 21.51% above its 200-day moving average. Moreover, shares of Alere, which provides professional diagnostic products and services for infectious and cardiometabolic disease, and toxicology in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 81.07.
On April 11th, 2017, Alere announced that its Alere™ Reader, a diagnostic analyzer that can be used in both point-of-care and laboratory settings, has received 510(k) marketing clearance from the US Food and Drug Administration. The Alere Reader will be initially available for use with the BinaxNOW® Influenza A & B Card 2, with other lateral flow applications and assays to follow. The free research report on ALR is available at:
Gaithersburg, Maryland headquartered OpGen Inc.'s stock closed the day 6.67% higher at $1.12. A total volume of 352,909 shares was traded, which was above their three months average volume of 342,830 shares. The Company's shares have advanced 4.67% in the past month. The stock is trading 4.48% above its 50-day moving average. Additionally, shares of OpGen, which engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, have an RSI of 54.22.
On April 19th, 2017, OpGen announced that it will report its Q1 2017 financial results after close of market on Wednesday, April 26th, 2017. The Company's management team will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss its financial results and business progress. The live, listen-only webcast of the conference call may be accessed under the investors section of the Company's website. The complimentary report on OPGN can be downloaded at:
Shares in Mississauga, Canada headquartered Novadaq Technologies Inc. recorded a trading volume of 320,608 shares. The stock ended yesterday's trading session 0.55% higher at $7.30. The Company's shares have advanced 9.28% in the previous three months and 2.96% on an YTD basis. The stock is trading below its 50-day moving average by 1.46%. Furthermore, shares of Novadaq Technologies, which develops, manufactures, and markets fluorescence imaging products for use by surgeons in the operating room and other clinical settings in the US and internationally, have an RSI of 43.39.
On April 19th, 2017, Novadaq Technologies announced that it will release financial results for Q1 2017 after the close of trading on Wednesday, May 03rd, 2017. The Company's management team will host a corresponding conference call beginning at 4:30 p.m. ET on the same day. A live and archived webcast of the event will be available under the "Investor Relations" section of the Company's website. Visit us today and download our complete research report on NVDQ for free at:
Raleigh, North Carolina headquartered PRA Health Sciences Inc.'s stock finished Tuesday's session 0.18% higher at $65.41. A total volume of 1.22 million shares was traded, which was above their three months average volume of 491,050 shares. The Company's shares have advanced 5.93% in the last one month, 20.15% over the previous three months, and 18.67% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.03% and 18.38%, respectively. Additionally, shares of PRA Health Sciences, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 63.93.
On April 17th, 2017, PRA Health Sciences announced that it will host its Q1 2017 conference call on Wednesday, April 26th, 2017, at 9:00 a.m. ET to discuss the results and guidance with members of the investment community. A live audio broadcast will be available under the investor relations section of the Company's website. Get free access to your technical report on PRAH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA